Back
ESC Premium Access

Time to discontinuation of non-vitamin k antagonist oral anticoagulants in patients with non-valvular atrial fibrillation

Session: Poster Session 5 - Atrial fibrillation and oral anticoagulation 1
Topic: Oral Anticoagulation
Speaker: Doctor A. Ruigomez (Madrid, ES)
Event: ESC Congress 2019

Congress Presentation

Add to my library

Like

About the speaker

Doctor Ana Ruigomez

Spanish Research Center Pharmacoepidemologic (CEIFE), Madrid (Spain)
0 follower

13 more presentations in this session

Oral anticoagulants and their effect on kidneys function, is warfarin safe?

Speaker: Associate Professor T. Novikova (Saint Petersburg, RU)

Access
Abstract
Slides
Like
Thumbnail

Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in newly diagnosed non-valvular atrial fibrillation.

Speaker: Doctor L. Bergamaschi (Bologna, IT)

Access
Abstract
Slides
Like
Thumbnail

Inappropriate dosing of non-vitamin K oral anticoagulants (NOACs) in atrial fibrillation patients in Europe

Speaker: Ms I. Palau (London, GB)

Access
Abstract
Like
Thumbnail

Patients with atrial fibrillation exhibit a systemic prothrombotic state attributable to impaired endogenous fibrinolysis

Speaker: Doctor Y. Gue (Liverpool, GB)

Access
Abstract
Slides
Like
Thumbnail

Concomitant oral anticoagulant and antidepressant therapy in patients with atrial fibrillation and risk of stroke and bleeding: a population based cohort study

Speaker: Professor P. Hjemdahl (Stockholm, SE)

Access
Abstract
Like
Thumbnail

Access the full session

Poster Session 5 - Atrial fibrillation and oral anticoagulation 1

Speakers: Doctor A. Ruigomez, Associate Professor T. Novikova, Doctor L. Bergamaschi, Ms I. Palau, Doctor Y. Gue...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources